卵巢癌PARP抑制剂治疗期间患者自付费用分析
该回顾性队列研究基于MarketScan保险索赔数据库,纳入2014-2017年接受奥拉帕利、尼拉帕利或芦卡帕利治疗的503例卵巢癌患者,发现83%的患者在PARP抑制剂治疗期间有自付支出;PARP抑制剂月均自付305美元,占每月总自付费用的44.8%,全部医疗月均自付470美元,估计占家庭月收入的8.7%。
要点
- 83%卵巢癌患者PARP抑制剂治疗期间存在自付费用。
- PARP抑制剂月均自付305美元,占每月总自付的44.8%。
- 全部医疗月均自付470美元,估占家庭月收入8.7%。
核心结论
- 卵巢癌患者PARP抑制剂治疗期间可能面临高额自付费用,但其他医疗服务的自付费用总和常更高。
- 医疗支出消耗了患者家庭收入的很大比例,治疗前和治疗期间均存在高自付负担。
研究设计与样本
- 回顾性队列研究,使用MarketScan保险索赔数据库。
- 纳入2014-2017年接受奥拉帕利、尼拉帕利或芦卡帕利治疗的503例卵巢癌患者,中位年龄55岁(IQR 50-62)。
主要发现
- 83%的患者在PARP抑制剂治疗期间有自付支出,中位治疗持续时间124天(IQR 66-240)。
- PARP抑制剂月均自付305美元(SD 2275),占每月总自付的44.8%(SD 34.8%)。
- 其他医疗服务月均自付165美元(SD 769),保险计划月均支付PARP抑制剂12661美元(SD 15668)。
- 全部医疗月均自付470美元(SD 2407),估计占家庭月收入的8.7%。
- PARP抑制剂治疗前12个月月均自付3110美元(SD 6987)。
临床怎么用
- 临床医生应关注卵巢癌患者PARP抑制剂治疗期间的自付费用负担。
- 与患者讨论治疗费用时,需考虑PARP抑制剂及其他医疗服务(如门诊、化验、影像)的自付支出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: More patients with ovarian cancer are being treated with poly(adenosine diphosphate-ribose) polymerase inhibitors because regulatory agencies have granted these drugs new approvals for a variety of treatment indications. However, poly(adenosine diphosphate-ribose) polymerase inhibitors are expensive. When administered as a maintenance therapy, these drugs may be administered for months or years. How much of this cost patients experience as out-of-pocket spending is unknown. OBJECTIVE: This study aimed to estimate the out-of-pocket spending that patients experience during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment and to characterize which healthcare services account for that spending. STUDY DESIGN: A retrospective cohort study was performed with a sample of patients with ovarian cancer treated between 2014 and 2017 with olaparib, niraparib, or rucaparib. Patients were identified using MarketScan, a health insurance claims database. All insurance claims during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment were collected. The primary outcome variable was the patients' out-of-pocket spending (copayment, coinsurance, and deductibles) during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment for the medication itself. Other outcomes of interest included out-of-pocket spending for other healthcare services, the types and frequency of other healthcare services used, health plan spending, the estimated proportion of patients' household income used each month for healthcare, and patients' out-of-pocket spending immediately before poly(adenosine diphosphate-ribose) polymerase inhibitor treatment. RESULTS: We identified 503 patients with ovarian cancer with a median age of 55 years (interquartile range, 50-62 years); 83% of those had out-of-pocket spendings during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment. The median treatment duration was 124 days (interquartile range, 66-240 days). The mean out-of-pocket spending for poly(adenosine diphosphate-ribose) polymerase inhibitors was $305 (standard deviation, $2275) per month. On average, this accounted for 44.8% (standard deviation, 34.8%) of the patients' overall monthly out-of-pocket spending. The mean out-of-pocket spending for other healthcare services was $165 (standard deviation, $769) per month. Health plans spent, on average, $12,661 (standard deviation, $15,668) per month for poly(adenosine diphosphate-ribose) polymerase inhibitors and $7108 (standard deviation, $15,254) per month for all other healthcare services. The cost sharing for office visits, laboratory tests, and imaging studies represented the majority of non-poly(adenosine diphosphate-ribose) polymerase inhibitor treatment out-of-pocket spending. The average amount patients paid for all healthcare services per month during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment was $470 (standard deviation, $2407), which was estimated to be 8.7% of the patients' monthly household income. The mean out-of-pocket spending in the 12 months before poly(adenosine diphosphate-ribose) polymerase inhibitor treatment was $3110 (standard deviation, $6987). CONCLUSION: Patients can face high out-of-pocket costs for poly(adenosine diphosphate-ribose) polymerase inhibitors, although the sum of cost sharing for other healthcare services used during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment is often higher. The spending on healthcare costs consumes a large proportion of these patients' household income. Patients with ovarian cancer experience high out-of-pocket costs for healthcare, both before and during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment.
引用
- Harrison RF, Fu S, Sun CC, et al. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. Am J Obstet Gynecol. 2021. PMID: 33549538. doi:10.1016/j.ajog.2021.01.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。